Ryoji Kato

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 978 citations

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi et al. · Clinical Cancer Research · 2020 · 233 citations

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura et al. · Clinical Cancer Research · 2018 · 160 citations

KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura et al. · Clinical Cancer Research · 2021 · 97 citations · Full text

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification

Naoki Takegawa, Junji Tsurutani, Hisato Kawakami et al. · International Journal of Cancer · 2019 · 89 citations · Full text